February 28, 2018 / 12:42 PM / in 8 months

BRIEF-Mabvax Therapeutics Reports Positive Safety Results From Initial Cohort Of MVT-1075

Feb 28 (Reuters) - Mabvax Therapeutics Holdings Inc :

* MABVAX THERAPEUTICS REPORTS POSITIVE SAFETY RESULTS FROM INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS

* MABVAX THERAPEUTICS HOLDINGS INC - ACHIEVED PRIMARY OBJECTIVES IN EARLY-STAGE CLINICAL TRIAL OF NOVEL RADIOIMMUNOTHERAPY PRODUCT MVT-1075 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below